https://apnews.com/37bd49fa05908f2709df316df3ba7a10

Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.

The shots could begin early next month — with the first children in line fully protected by Christmas — if regulators give the go-ahead.